| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Grace Therapeutics, Inc.'s insiders have accumulated 300,218 shares worth roughly $616K on balance. In the past 30 days, 1 insider bought and 0 sold. Recent activity has leaned to the buy side.
Leading the buying is Opaleye Management Inc. (10% Owner), now holding an estimated $5.5M in GRCE.
Classified under Biotechnology (Health Care sector), GRCE's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.95M | $5.54M | +158.3K | |
| CEO | 121.4K | $259.7K | - | |
| Other | 54.7K | - | - | |
| VP | 35.8K | - | - | |
| Other | 33.7K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2023 | Olds Donald | Director | Buy | 381 | $2.05 | $781.05 | New | -0.5% | +27.2% |